Detalles de la búsqueda
1.
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
N Engl J Med
; 386(1): 35-46, 2022 01 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34752019
2.
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.
Vaccines (Basel)
; 12(2)2024 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38400102
3.
Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
Vaccine
; 41(13): 2137-2146, 2023 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36828719
4.
Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old.
Vaccine
; 41(28): 4190-4198, 2023 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37244809
5.
Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease.
Hum Vaccin Immunother
; 18(6): 2126253, 2022 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36368038
6.
In vitro generation of tumor specific T cells that recognize a shared antigen of AML: molecular characterization of TCR genes.
Leuk Res
; 31(2): 195-202, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16750565
7.
Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term culture.
Leuk Res
; 26(2): 191-201, 2002 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-11755469
8.
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. An open-label trial.
Hum Vaccin Immunother
; 10(7): 1850-8, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25424792
Resultados
1 -
8
de 8
1
Próxima >
>>